Regencell Bioscience Holdings Stock Performance
| RGC Stock | USD 11.11 0.17 1.51% |
The company holds a Beta of 1.43, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Regencell Bioscience will likely underperform. At this point, Regencell Bioscience has a negative expected return of -0.22%. Please make sure to check Regencell Bioscience's treynor ratio, accumulation distribution, price action indicator, as well as the relationship between the potential upside and day median price , to decide if Regencell Bioscience performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Regencell Bioscience Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain rather sound which may send shares a bit higher in December 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
| Begin Period Cash Flow | 1.6 M | |
| Total Cashflows From Investing Activities | 5.2 M |
Regencell | Build AI portfolio with Regencell Stock |
Regencell Bioscience Relative Risk vs. Return Landscape
If you would invest 1,405 in Regencell Bioscience Holdings on August 29, 2025 and sell it today you would lose (294.00) from holding Regencell Bioscience Holdings or give up 20.93% of portfolio value over 90 days. Regencell Bioscience Holdings is generating negative expected returns assuming volatility of 5.336% on return distribution over 90 days investment horizon. In other words, 47% of stocks are less volatile than Regencell, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Regencell Bioscience Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Regencell Bioscience's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Regencell Bioscience Holdings, and traders can use it to determine the average amount a Regencell Bioscience's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0422
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RGC |
Estimated Market Risk
| 5.34 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Regencell Bioscience is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Regencell Bioscience by adding Regencell Bioscience to a well-diversified portfolio.
Regencell Bioscience Fundamentals Growth
Regencell Stock prices reflect investors' perceptions of the future prospects and financial health of Regencell Bioscience, and Regencell Bioscience fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Regencell Stock performance.
| Return On Equity | -0.55 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 5.77 B | ||||
| Shares Outstanding | 494.49 M | ||||
| Price To Earning | 26.21 X | ||||
| Price To Book | 1,188 X | ||||
| EBITDA | (3.62 M) | ||||
| Cash And Equivalents | 59.41 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 85.74 K | ||||
| Debt To Equity | 0.07 % | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (4 M) | ||||
| Earnings Per Share | (0.01) X | ||||
| Total Asset | 8.44 M | ||||
| Retained Earnings | (21.62 M) | ||||
| Current Asset | 438.2 M | ||||
| Current Liabilities | 551.3 M | ||||
About Regencell Bioscience Performance
By analyzing Regencell Bioscience's fundamental ratios, stakeholders can gain valuable insights into Regencell Bioscience's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Regencell Bioscience has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Regencell Bioscience has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.Things to note about Regencell Bioscience performance evaluation
Checking the ongoing alerts about Regencell Bioscience for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Regencell Bioscience help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Regencell Bioscience generated a negative expected return over the last 90 days | |
| Regencell Bioscience has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (4.36 M) with profit before taxes, overhead, and interest of 0. | |
| Regencell Bioscience Holdings has about 59.41 K in cash with (4 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Regencell Bioscience has a poor financial position based on the latest SEC disclosures | |
| Roughly 89.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Regencell Bioscience's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Regencell Bioscience's stock is overvalued or undervalued compared to its peers.
- Examining Regencell Bioscience's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Regencell Bioscience's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Regencell Bioscience's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Regencell Bioscience's stock. These opinions can provide insight into Regencell Bioscience's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |